Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders
Open Access
- 16 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 47 (2) , 485-494
Abstract
Studies on the long-term development and early predictors of treatment-resistant schizophrenia (TRS) and clozapine-resistant TRS (CR-TRS) in patients with first-episode schizophrenia-spectrum disorders (FES) are limited and have not considered the impact of early intervention services (EIS). This study aimed to explore the development of TRS and CR-TRS among patients with FES over 12 years of follow-up. Of the 1234 patients with FES, 15% developed TRS. A total of 450 patients with schizophrenia or schizoaffective disorder were included in a nested case-control study (157 TRS and 293 non-TRS). Younger age of onset, poorer premorbid social adjustment during adulthood, longer duration of first episode, a greater number of relapses, and a higher antipsychotic dose in the first 24 months were associated with earlier TRS. CR-TRS patients, constituting 25% of TRS patients, had a poorer premorbid social adjustment in late adolescence and longer delay before clozapine initiation compared with non-CR-TRS. CR-TRS had poorer clinical and functional outcomes at 12-year follow-up. However, TRS patients on clozapine had a lower mortality rate compared with non-TRS patients. EIS did not have a significant impact on the development of TRS, but patients in the EIS group had a shorter delay of clozapine initiation. Results suggested that neurodevelopmental factors, early clinical characteristics, and requirement for higher antipsychotic dose may be associated with TRS development, highlighting multiple pathways leading to this form of illness. Specific interventions including relapse prevention and early initiation of clozapine during the early course of illness may reduce the rate of TRS and improve patient outcomes.Keywords
Funding Information
- Health and Medical Research Fund
- Hong Kong (11121721)
This publication has 47 references indexed in Scilit:
- Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) studyThe British Journal of Psychiatry, 2011
- Early intervention for psychosis in Hong Kong – the EASY programmeEarly Intervention in Psychiatry, 2010
- International Consensus Study of Antipsychotic DosingAmerican Journal of Psychiatry, 2010
- Premorbid functioning of patients with first-episode nonaffective psychosis: A comparison of deterioration in academic and social performance, and clinical correlates of Premorbid Adjustment Scale scoresSchizophrenia Research, 2008
- Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?International Clinical Psychopharmacology, 2008
- Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugsSchizophrenia Research, 2007
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophreniaThe World Journal of Biological Psychiatry, 2006
- Size of burden of schizophrenia and psychotic disordersEuropean Neuropsychopharmacology, 2005
- Remission in Schizophrenia: Proposed Criteria and Rationale for ConsensusAmerican Journal of Psychiatry, 2005
- Treatment-Resistant Schizophrenia - The Role of ClozapineCurrent Medical Research and Opinion, 1997